vincerx_logo.png
Vincerx to Present Three Posters at the American Association for Cancer Research (AACR) Annual Meeting 2024
March 05, 2024 16:31 ET | Vincerx Pharma, Inc.
PALO ALTO, Calif., March 05, 2024 (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc. (Nasdaq: VINC), a biopharmaceutical company aspiring to address the unmet medical needs of patients with cancer through...
logo vincerx-pharma_color.png
Vincerx Pharma Announces Compelling Clinical Efficacy of Enitociclib in Combination with Venetoclax and Prednisone in Lymphoma
January 07, 2024 15:00 ET | Vincerx Pharma, Inc.
Investigators from the National Institutes of Health (NIH) report 2 partial responses (PR) in 3 peripheral T-cell lymphoma (PTCL) patients and 1 PR in 2 double-hit diffuse large b-cell lymphoma...
logo vincerx-pharma_color.png
Vincerx Pharma Presents Preclinical VIP943 and VIP924 Posters at ASH 2023
December 10, 2023 12:00 ET | Vincerx Pharma, Inc.
  Poster on VIP943, a novel CD123-targeted antibody-drug conjugate (ADC) from our VersAptx™ platform, showcases selectivity, activity, and safety of VIP943 Poster on VIP924, a first-in-class...
logo vincerx-pharma_color.png
Vincerx Pharma Reports Third Quarter 2023 Financial Results and Provides Corporate Update
November 14, 2023 07:00 ET | Vincerx Pharma, Inc.
Phase 1 dose escalation for VIP943 - first antibody-drug conjugate (ADC) from VersAptx™, versatile and adaptable, next-generation bioconjugation platform - moves quickly into 2nd cohort Phase 1 dose...
logo vincerx-pharma_color.png
Vincerx Pharma To Present Three Posters at ASH 2023 in December
November 02, 2023 09:10 ET | Vincerx Pharma, Inc.
VIP943 poster supports selectivity and safety of lead CD123 ADC, VIP943, currently in Phase 1 VIP924 poster shows this novel CXCR5-ADC compares favorably with other ADCs in clinical development ...
logo vincerx-pharma_color.png
Vincerx Pharma to Participate at the Cantor Fitzgerald Global Healthcare Conference 2023
September 19, 2023 07:00 ET | Vincerx Pharma, Inc.
PALO ALTO, Calif., Sept. 19, 2023 (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc. (Nasdaq: VINC), a biopharmaceutical company aspiring to address the unmet medical needs of patients with cancer through...
logo vincerx-pharma_color.png
Vincerx Pharma Doses First Patient in the Phase 1 Clinical Trial Evaluating VIP943
September 14, 2023 07:00 ET | Vincerx Pharma, Inc.
PALO ALTO, Calif., Sept. 14, 2023 (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc. (Nasdaq: VINC)(“Vincerx”), a biopharmaceutical company aspiring to address the unmet medical needs of patients with cancer...
logo vincerx-pharma_color.png
Vincerx Pharma Announces FDA Clearance of IND for VIP943
August 22, 2023 07:30 ET | Vincerx Pharma, Inc.
Phase 1 trial expected to begin in early Q4 2023 VIP943 is Vincerx’ first candidate from next-generation ADC platform and its second IND clearance within 8 months, highlighting Vincerx’s development...
logo vincerx-pharma_color.png
Vincerx Pharma Reports Second Quarter 2023 Financial Results and Provides Corporate Update
August 07, 2023 09:25 ET | Vincerx Pharma, Inc.
IND Application filed for potential best-in-class ADC, VIP943; Phase 1 trial expected to begin Q4 2023 Enrollment continues in Phase 1 dose escalation study for VIP236, a first-in-class SMDC ...
logo vincerx-pharma_color.png
Vincerx Pharma Reports First Quarter 2023 Financial Results and Provides Corporate Update
May 11, 2023 16:05 ET | Vincerx Pharma, Inc.
Enrollment continues in Phase 1 dose escalation study for VIP236, a first-in-class αvβ3 small molecule drug conjugate (SMDC) for the treatment of solid tumors IND filing for VIP943, a next-generation...